Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy-Reference-Cited by-同舟云学术

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

Published:2011-05-16 Issue:23 Volume:117 Page:5351-5358
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Reardon David A.,Desjardins Annick,Peters Katherine B.,Vredenburgh James J.,Gururangan Sridharan,Sampson John H.,McLendon Roger E.,Herndon James E.,Coan April,Threatt Stevie,Friedman Allan H.,Friedman Henry S.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference56 articles.

1. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial;Stupp;Lancet Oncol.,2009

2. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme;Ballman;Neuro Oncol.,2007

3. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas;Lamborn;Neuro Oncol.,2008

4. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials;Wong;J Clin Oncol.,1999

5. Tumor angiogenesis: a quantitative method for histologic grading;Brem;J Natl Cancer Inst.,1972

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug therapy for brain glioblastoma;Onkologiya. Zhurnal imeni P.A.Gertsena;2023

2. Repurposing drugs in glioblastoma;New Insights Into Glioblastoma;2023

3. Updates in the Management of Recurrent Glioblastoma Multiforme;Journal of Neurological Surgery Part A: Central European Neurosurgery;2022-06-30

4. Brain and Spinal Cord Tumors;Fundamentals of Cancer Detection, Treatment, and Prevention;2022-05-13

5. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas;Journal of Neuro-Oncology;2021-10-24